



## DAFTAR PUSTAKA

- Amelia, S. (2011). *PENGELOLAAN SPESIMEN UNTUK PEMERIKSAAN MIKROBIOLOGI KLINIK DISUSUN OLEH*.
- Chaplin, D. D. (2010). Overview of the immune response. *Journal of Allergy and Clinical Immunology*, 125(2 SUPPL. 2). <https://doi.org/10.1016/j.jaci.2009.12.980>
- Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. *Journal of Clinical Investigation*, 130(5), 2620–2629. <https://doi.org/10.1172/JCI137244>
- Cleland, D., & Franki, A. (2020). *Procalcitonin*. StatPearls Publishing.
- de Bruyn, A., Verellen, S., Bruckers, L., Geebelen, L., Callebaut, I., de Pauw, I., Stessel, B., & Dubois, J. (2022). Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. *BMC Infectious Diseases*, 22(1). <https://doi.org/10.1186/s12879-022-07192-x>
- di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. In *International Journal of Environmental Research and Public Health* (Vol. 17, Issue 8). MDPI AG. <https://doi.org/10.3390/ijerph17082690>
- Gautam, S., Cohen, A. J., Stahl, Y., Valda Toro, P., Young, G. M., Datta, R., Yan, X., Ristic, N. T., Bermejo, S. D., Sharma, L., Restrepo, M. I., & dela Cruz, C. S. (2020). Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. *Thorax*, 75(11), 974–981. <https://doi.org/10.1136/thoraxjnl-2020-214896>
- Gupta, A., Madhavan, M. v., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., Freedberg, D. E., Kirtane, A. J., Parikh, S. A., Maurer, M. S., Nordvig, A. S., Accili, D., Bathon, J. M., Mohan, S., Bauer, K. A., ... Landry, D. W. (2020). Extrapulmonary manifestations of COVID-19. In *Nature Medicine* (Vol. 26, Issue 7, pp. 1017–1032). Nature Research. <https://doi.org/10.1038/s41591-020-0968-3>
- Hu, R., Han, C., Pei, S., Yin, M., & Chen, X. (2020). Procalcitonin levels in COVID-19 patients. *International Journal of Antimicrobial Agents*, 56(2). <https://doi.org/10.1016/j.ijantimicag.2020.106051>
- Khan, F. Y. (2017). High Serum Procalcitonin: Interpret with Caution. *Clinical Microbiology: Open Access*, 06(02). <https://doi.org/10.4172/2327-5073.1000e141>
- Lee, H. (2013). Procalcitonin as a biomarker of infectious diseases. *Korean Journal of Internal Medicine*, 28(3), 285–291. <https://doi.org/10.3904/kjim.2013.28.3.285>



- Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang, Q., & Wu, J. (2020). *Coronavirus infections and immune responses*. *J Med Virol*.
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., ... Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *New England Journal of Medicine*, 382(13), 1199–1207. <https://doi.org/10.1056/nejmoa2001316>
- Mangogna, A., Agostinis, C., Ricci, G., Romano, F., & Bulla, R. (2019). Overview of procalcitonin in pregnancy and in pre-eclampsia. In *Clinical and Experimental Immunology* (Vol. 198, Issue 1, pp. 37–46). Blackwell Publishing Ltd. <https://doi.org/10.1111/cei.13311>
- May, M., Chang, M., Dietz, D., Shoucri, S., Laracy, J., Sobieszczyk, M. E., Uhlemann, A. C., Zucker, J., & Kubin, C. J. (2021). Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with coronavirus disease 2019. *Antimicrobial Agents and Chemotherapy*, 65(4). <https://doi.org/10.1128/AAC.02167-20>
- Meisner, M. (2014). Update on procalcitonin measurements. In *Annals of Laboratory Medicine* (Vol. 34, Issue 4, pp. 263–273). Seoul National University. <https://doi.org/10.3343/alm.2014.34.4.263>
- Murphy, K. (Kenneth M. ), Weaver, C., & Janeway, C. (n.d.). *Janeway's immunobiology*.
- Murray PR, R. K. and P. M. (2021). Immune Responses to Infectious Agents. In *Medical Microbiology* (1st ed., Vol. 10, pp. 83–103). Elsevier Inc.
- Paudel, R., Dogra, P., Montgomery-Yates, A. A., & Yataco, A. C. (2020). Procalcitonin: A promising tool or just another overhyped test? In *International Journal of Medical Sciences* (Vol. 17, Issue 3, pp. 332–337). Ivyspring International Publisher. <https://doi.org/10.7150/ijms.39367>
- Richards, O., Pallmann, P., King, C., Cheema, Y., Killick, C., Thomas-Jones, E., Harris, J., Bailey, C., & Szakmany, T. (2021). Procalcitonin increase is associated with the development of critical care-acquired infections in covid-19 ards. *Antibiotics*, 10(11). <https://doi.org/10.3390/antibiotics10111425>
- Ripa, M., Galli, L., Poli, A., Oltolini, C., Spagnuolo, V., Mastrangelo, A., Muccini, C., Monti, G., de Luca, G., Landoni, G., Dagna, L., Clementi, M., Rovere Querini, P., Ciceri, F., Tresoldi, M., Lazzarin, A., Zangrillo, A., Scarpellini, P., Castagna, A., ... Vinci, C. (2021). Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. *Clinical Microbiology and Infection*, 27(3), 451–457. <https://doi.org/10.1016/j.cmi.2020.10.021>
- Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., Sigfrid, L., Harrison, E. M., Docherty, A. B., de Silva, T. I., Egan, C., Pius, R., Hardwick, H. E., Merson, L., Girvan, M., Dunning, J., Nguyen-Van-Tam, J. S., Openshaw, P. J. M., Baillie, J. K., ... Young, P. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK



- study: a multicentre, prospective cohort study. *The Lancet Microbe*, 2(8), e354–e365. [https://doi.org/10.1016/S2666-5247\(21\)00090-2](https://doi.org/10.1016/S2666-5247(21)00090-2)
- Samsudin, I., & Vasikaran, S. D. (2017). Clinical Utility and Measurement of Procalcitonin. In *Clin Biochem Rev* (Vol. 59, Issue 2).
- Satuan Tugas Penanganan COVID-19. (2021). *Peta Sebaran*. <https://covid19.go.id/peta-sebaran>
- Sigakis, M. J. G., Jewell, E., Maile, M. D., Cinti, S. K., Bateman, B. T., & Engoren, M. (2019). Culture-Negative and Culture-Positive Sepsis: A Comparison of Characteristics and Outcomes. *Anesthesia and Analgesia*, 129(5), 1300–1309. <https://doi.org/10.1213/ANE.0000000000004072>
- Taysi, M., Yildirim, F., Simsek, M., Dural, H., & Sencan, I. (2023). Secondary Infections in Critical Patients with COVID-19 Associated ARDS in the ICU: Frequency, Microbiologic Characteristics and Risk Factors. *Journal of the College of Physicians and Surgeons Pakistan*, 33(2), 181–187. <https://doi.org/10.29271/jcpsp.2023.02.181>
- Vazzana, N., Dipaola, F., & Ognibene, S. (2022). Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. *Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine*, 77(2), 268–272. <https://doi.org/10.1080/17843286.2020.1824749>
- Vijay, S., Bansal, N., Rao, B. K., Veerarghavan, B., Rodrigues, C., Wattal, C., Goyal, J. P., Tadepalli, K., Mathur, P., Venkateswaran, R., Venkatasubramanian, R., Khadanga, S., Bhattacharya, S., Mukherjee, S., Baveja, S., Sistla, S., Panda, S., & Walia, K. (2021). Secondary infections in hospitalized COVID-19 patients: Indian experience. *Infection and Drug Resistance*, 14, 1893–1903. <https://doi.org/10.2147/IDR.S299774>
- Vijayan, A. L., Ravindran, S., Saikant, R., Lakshmi, S., Kartik, R., & Manoj, G. (2017). Procalcitonin: A promising diagnostic marker for sepsis and antibiotic therapy. In *Journal of Intensive Care* (Vol. 5, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s40560-017-0246-8>
- World Health Organization. (2021). *Coronavirus disease (COVID-19) pandemic*. <https://covid19.who.int/>
- Wu, S. C., Liang, C. X., Zhang, Y. L., & Hu, W. P. (2020). Elevated serum procalcitonin level in patients with chronic kidney disease without infection: A case-control study. *Journal of Clinical Laboratory Analysis*, 34(2). <https://doi.org/10.1002/jcla.23065>
- Yang, L., Lin, Y., Wang, J., Song, J., Wei, B., Zhang, X., Yang, J., & Liu, B. (2021). Comparison of clinical characteristics and outcomes between positive and negative blood culture septic patients: A retrospective cohort study. *Infection and Drug Resistance*, 14, 4191–4205. <https://doi.org/10.2147/IDR.S334161>
- Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. In *Clinical Immunology* (Vol. 215). Academic Press Inc. <https://doi.org/10.1016/j.clim.2020.108427>
- Zhang, H., Zhang, Y., Wu, J., Li, Y., Zhou, X., Li, X., Chen, H., Guo, M., Chen, S., Sun, F., Mao, R., Qiu, C., Zhu, Z., Ai, J., & Zhang, W. (2020). Risks and features of secondary infections in severe and critical ill COVID-19 patients.



UNIVERSITAS  
GADJAH MADA

**Kadar Procalcitonin sebagai Prediktor Infeksi Sekunder pada Pasien COVID-19 Rawat Inap**  
WINDA ERNIA, dr. Heni Retno Wulan, M.Kes, Sp.PD-KP; dr. Rizka Humardewayanti Asdie, Sp.PD - KPTI  
Universitas Gadjah Mada, 2023 | Diunduh dari <http://etd.repository.ugm.ac.id/>

*Emerging Microbes and Infections*, 9(1), 1958–1964.  
<https://doi.org/10.1080/22221751.2020.1812437>